The contribution of single antigen measles, mumps and rubella vaccines to immunily to these infections in England and Wales

Sonnenberg, Pam; Crowcroft, Natasha S.; White, Joanne M.; Ramsay, Mary E.
September 2007
Archives of Disease in Childhood;Sep2007, Vol. 92 Issue 9, p786
Academic Journal
Objective: To obtain information on the use of single antigen measles, mumps and rubella vaccines to improve estimates of population immunity and help predict outbreaks. Design: We requested information from providers of single antigen vaccines and from the Medicine and Healthcare products Regulatory Agency on requests for importation of single antigen measles and mumps vaccines. Setting: England and Wales. Main outcome measures: Number of doses of single measles, mumps and rubella vaccine, by age of child (in months), year given and area of residence, and number of children who have received all three single vaccinations. Results: Of 27 providers identified, 13 held single site clinics: nine were individual general practitioners and five held clinics at multiple sites. Data were received from 9/27 (33%) providers operating 40⁄74 (54%) clinic sites. We received information on 60 768 vaccinations administered by single vaccine providers and 269 917 doses requested for importation. For children born in 2001⁄2002, the minimum estimates for the proportion who received single measles vaccine are 1.7% in 2001 and 2.1% in 2002, with a reasonable maximum estimate of 5.6% over the 2 years. For single mumps vaccine, the minimum estimates are 0.3% in 2001 and 0.02% in 2002, with a maximum estimate of 4.0%. Conclusion: The contribution of single vaccines to immunity is small in comparison to that of the combined measles, mumps and rubella vaccine (MMR). For recent birth cohorts this contribution could increase routine coverage for measles-containing vaccines by around 2%, still below the level of immunity required to sustain elimination.


Related Articles

  • Booster shot is ‘crucial’.  // GP: General Practitioner;2/11/2002, p4 

    Examines the adequate immunity of measles, mumps and rubella booster in Great Britain.

  • New data shows uptake of MMR is now rising.  // GP: General Practitioner;10/6/2003, p29 

    Measles, mumps and rubella (MMR) uptake is on the rise, according to the latest Health Protection Agency sentinel data. The data shows that uptake of the vaccine among children aged 16 months was 70.9 per cent for August, representing a rise of 6.4 percentage points over the past six months....

  • Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic... Roberts, Richard J.; Sandifer, Quentin D. // BMJ: British Medical Journal (International Edition);6/24/95, Vol. 310 Issue 6995, p1629 

    Investigates the reasons for poor uptake of immunization. Possible side effects of measles, mumps and rubella vaccine in a catch up immunization campaign during a community outbreak of measles; Descriptive study of reasons for non-immunization and retrospective cohort study of side effects of...

  • Measles, Mumps and Rubella Vaccine, Autism and Inflammatory Bowel Disease: Advising Concerned Parents. Elliman, D.A.C.; Bedford, H.E. // Pediatric Drugs;2002, Vol. 4 Issue 10, p631 

    Measles, mumps and rubella (MMR) vaccine has been used for almost 30 years in the US, 20 years in Sweden and Finland, and over 10 years in most of the rest of Europe. During this time, it has brought about a dramatic reduction in the morbidity and mortality due to measles and mumps, as well as a...

  • This won't hurt... Day, Michael // New Scientist;03/07/98, Vol. 157 Issue 2124, p4 

    Reports that according to a study, autism is a rare side effect resulting from the immunization of children, against measles, mumps and rubella. Indepth look at the safety of multi-component vaccines; Reference to a study in which children were given the measles-mumps-rubella triples vaccine;...

  • Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groups. Vandermeulen, Corinne; Roelants, Mathieu; Theeten, Heidi; Van Damme, Pierre; Hoppenbrouwers, Karel // European Journal of Pediatrics;Oct2008, Vol. 167 Issue 10, p1161 

    WHO-Europe's goal is to eliminate measles and rubella by 2010 which will require a coverage rate of 95% for both MMR-vaccine doses. Belgian recommendations include a first MMR vaccine at 12 months and a second at 10-12 years of age. To survey MMR vaccination coverage, EPI two-stage random...

  • Exploring the evidence surrounding the debate on MMR and autism. Purssell, Edward // British Journal of Nursing;7/22/2004, Vol. 13 Issue 14, p834 

    Autism is a poorly understood condition that would appear to be on the increase. There is currently much concern about a possible link between the measles, mumps and rubella (MMR) vaccination and autism which has resulted in a substantial reduction in the uptake of MMR, putting children at risk...

  • MMR vaccine/thiomersal no link with autism: time to find real cause.  // Reactions Weekly;6/5/2004, Issue 1004, p2 

    Discusses research being done on the link between the measles, mumps and rubella virus vaccine and the vaccine preservative thiomersal with autism. Reference to a study by the U.S. Institute of Medicine of the National Academies released on May 18, 2004; Epidemiological studies covered in the...

  • USPJEÅ NOST PREVENCIJE I KONTROLE VAKCINO PREVENTIBILNIH OBOLJENJA U CRNOJ GORI. Laušević, Dragan // Medicinski Zapisi / Medical Essays;2009, p39 

    The aim of this paper is to analyze achieved results in controlling of vaccine preventable diseases in Montenegro in relation to primary immunization coverage of the target population with DTP3, OPV3 i MMR1. Method: The analysis of achieved results in controlling vaccine preventable diseases in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics